Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: An exploratory analysis from a randomized, double-blind, active-controlled trial

BMC Cancer

Volumn 9, Issue , 2009, Pages 311-

  Vansteenkiste, Johan ^a   Hedenus, Michael ^b   Gascon, Pere ^c   Bokemeyer, Carsten ^d   Ludwig, Heinz ^e   Vermorken, Jan ^f   Hamilton, Lisa ^g   Bridges, Ken ^h   Pujol, Beatriz ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SUNDSVALL HOSPITAL   (Sweden)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e WILHELMINEN HOSPITAL   (Austria)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g AMGEN LTD   (United Kingdom)

^h AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EMBOLISM; EXPLORATORY RESEARCH; FATIGUE; FEBRILE NEUTROPENIA; HEART ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349849380     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-311     Document Type: Article

References (32)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999, 91(19):1616-1634. 10.1093/jnci/91.19.1616, 10511589.
2. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003, 14(4):511-519. 10.1093/annonc/mdg167, 12649095.
3. Barbara JA. The rationale for pathogen-inactivation treatment of blood components. Int J Hematol 2004, 80(4):311-316. 10.1532/IJH97.04120, 15615254.
4. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 2004, 126(1):249-258. 10.1378/chest.126.1.249, 15249468.
5. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008, 168(21):2377-2381. 10.1001/archinte.168.21.2377, 19029504.
6. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006, 98(10):708-714.
7. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001, 19(11):2875-2882.
8. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003, 122(3):394-403. 10.1046/j.1365-2141.2003.04448.x, 12877666.
9. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19(11):2865-2874.
10. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002, 94(16):1211-1220.
11. Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006, 98(4):273-284.
12. Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF. Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008, 26(14):2342-2349. 10.1200/JCO.2007.15.0748, 18467726.
13. Aranesp® (Darbepoetin alfa) Package Insert. Amgen Inc., Breda, The Netherlands. 2008,
14. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006, 28(6):801-831. 10.1016/j.clinthera.2006.06.003, 16860166.
15. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43(2):258-270. 10.1016/j.ejca.2006.10.014, 17182241.
16. European public assessment reports for authorised medicinal products for human use. European Medicines Agency website. , http://www.emea.europa.eu/htms/human/epar/a.htm
17. electronic Medicines Compendium (eMC) website. , http://emc.medicines.org.uk
18. Aranesp® (Darbepoetin alfa) Package Insert. 2009, Amgen Inc., Thousand Oaks, CA.
19. Procrit® (Epoetin alfa) Package Insert. 2009, Centocor Ortho Biotech Products, L.P., Raritan, NJ.
20. Amgen announces interim results of Aranesp® "PREPARE" study in breast cancer patients [Amgen press release]. Nov 30, 2007. , http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2007&releaseI D=1083091
21. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1255-1260. 10.1016/S0140-6736(03)14567-9, 14575968.
22. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005, 23(25):5960-5972. 10.1200/JCO.2005.06.150, 16087945.
23. Overgaard J, Hoff C, Sand Hansen H, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen L, Evensen J. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)- the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial [abstract 6LB]. Eur J Cancer 2007, 4:7.
24. Smith RE, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008, 26:1040-1050. 10.1200/JCO.2007.14.2885, 18227526.
25. Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci JA, Begg AC. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008, 108(2):317-325. 10.1016/j.ygyno.2007.10.011, 2350198, 18037478.
26. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007, 25(9):1027-1032. 10.1200/JCO.2006.07.1514, 17312332.
27. Amgen Inc. in collaboration with Johnson & Johnson Pharmaceutical Research and Development, L.L.C.Background Information. For The Oncologic Drugs Advisory Comittee (ODAC) Meeting 13 March 2008. , http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-00-FDA-index .htm
28. Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). 2006, Rockville, MD: Agency for Healthcare Research and Quality., http://effectivehealthcare.ahrq.gov/repFiles/EPO%20Final.pdf
29. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373(9674):1532-1542. 10.1016/S0140-6736(09)60502-X, 19410717.
30. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299(8):914-924. 10.1001/jama.299.8.914, 18314434.
31. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA. Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia. J Clin Oncol 2009, 27(17):2838-2847. 10.1200/JCO.2008.19.1130, 19380447.
32. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004, 91(7):1229-35. 10.1038/sj.bjc.6602102, 15305188.